Tolerability of sumatriptan: clinical trials and post-marketing experience.
ABSTRACT Through December 1998, sumatriptan had been used to treat more than 236 million migraine attacks world-wide. In clinical trials alone, more than 88000 migraine patients had treated more than 300000 migraine attacks with sumatriptan, and 2000 normal healthy volunteers had been exposed to the drug. This paper describes the safety and tolerability profile of sumatriptan in three sections: adverse events reported in clinical trials, special issues, and spontaneous post-marketing reports of adverse reactions. Data from the extensive clinical trials programme coupled with information from nearly 10 years of experience in clinical practice demonstrate that sumatriptan is generally well-tolerated, with an acceptable benefit-risk ratio when used properly. Significant cardiovascular and cerebrovascular events are rare but have been observed. This fact highlights the need for careful patient selection and vigilant adherence to the prescribing recommendations for sumatriptan. The wealth of clinical trials and post-marketing information for sumatriptan may be useful in guiding prescribing decisions for members of this class of drugs.
[Show abstract] [Hide abstract]
ABSTRACT: In RT2B2C compounds with rare earths R and transition metals T superconductivity and antiferromagnetic order coexist with the magnetic ordering temperature TN being comparable with the superconducting transition temperature Tc. YPd2B2C has the largest Tc (23 K). RT2B2C superconductors show Fermi-surface nesting, multiband superconductivity and a remarkable gap anisotropy. In HoNi2B2C the competition between superconductivity and magnetism is most complex. In ErNi2B2C superconductivity coexists with weak ferromagnetism. DyNi2B2C is a superconducting antiferromagnet with TN>Tc. The magnetic order in RT2B2C is connected with 4f-orbital ordering (quadrupolar ordering) resulting in a lattice distortion below TN. Quadrupolar ordering has been reported for superconducting TmNi2B2C even at temperatures where this compound is not magnetically ordered. A square symmetry of single vortices and hexagonal-to-square transitions of the vortex lattice at certain applied magnetic fields are observed in RNi2B2C compounds (R=Y, Lu, Er, Tm) due to the four-fold symmetry of the Fermi velocity.Handbook on the Physics and Chemistry of Rare Earths 01/2007; 38:175-336. DOI:10.1016/S0168-1273(07)38004-5
[Show abstract] [Hide abstract]
ABSTRACT: BackgroundThe persistence of triptan use among newly prescribed users is low in the United States and European countries. However, triptan refill patterns in Asian primary care practices have not been well described.MethodsData from the National Health Insurance Research Database in Taiwan were used to conduct a retrospective cohort analysis from 2005 to 2008. All participants were followed for 2 years after receiving a new triptan prescription. Refill and 2-year retention rates of newly prescribed triptans were calculated, and predictors of the first triptan refill and 2-year retention were analyzed.ResultsOf the 13,951 participants with a new triptan prescription (99.9% sumatriptan), 67.4% were prescribed by a neurologist, 67.4% were prescribed at least one prophylactic agent for migraine. Of them, 34.3% adhered to the newly prescribed triptan at the first refill, 0.01% switched to another triptan, and 40.9% switched to a non-triptan acute migraine medication. The 2-year retention rate was 4.0%. The frequency of headache-related neurologic visits for 1 year before the index date, first prescription of triptan or other acute medications, first triptan prescription by a neurologist, and prophylactic use were associated with higher first refill rates. The frequency of headache-related neurologic visits 1 year before the index date and first triptan prescription by a neurologist were related to higher 2-year retention rates. Diabetes mellitus and first triptan prescription at a local medical clinic were associated with reduced probability of continued triptan use at the first refill and 2 years.ConclusionsSimilar to Western societies, the refill and 2-year retention rates were low in new users of triptans. Frequency of neurologic visits and triptan prescription by a neurologist were significant predictors of adherence.The Journal of Headache and Pain 08/2014; 15(1):48. DOI:10.1186/1129-2377-15-48 · 3.28 Impact FactorThis article is viewable in ResearchGate's enriched formatRG Format enables you to read in context with side-by-side figures, citations, and feedback from experts in your field.
Cephalalgia 08/2013; 34(1). DOI:10.1177/0333102413499647 · 4.12 Impact Factor